This publication’s primary purpose is to provide a compilation of actions to address malnutrition in all its forms, in a concise and user-friendly format to help in decision-making processes for integration of nutrition interventions in national health policies, strategies, and plans based on coun...try-specific needs and global priorities.
more
Le présent document énonce la première stratégie mondiale du secteur de la santé contre l’hépatite virale, une stratégie qui contribue à la réalisation du Programme de développement durable à l’horizon 2030.
Elle couvre les six premières années du plan d’action pour la santé... de l’après-2015, c’est-à-dire la période 2016-2021, en s’appuyant sur le document Prévention et lutte contre l’hépatite virale : cadre pour l’action mondiale et sur deux résolutions relatives à l’hépatite virale adoptées par l’Assemblée mondiale de la Santé en 2010 et en 2014.
Cette stratégie porte sur les cinq virus de l’hépatite (les hépatites A, B, C, D et E), en mettant plus spécialement l’accent sur les hépatites B et C en raison de la lourde charge relative qu’elles représentent pour la santé publique.
more
The potential for terrorist use of chemical agents is a noted concern highlighted by the Tokyo sarin gas attacks of 1995. The events of September 11, 2001, increased congressional attention towards reducing the vulnerability of the United States to such unconventional attacks. The
possibility that... terrorist groups might obtain insecure chemical weapons led to increased scrutiny of declared Libyan chemical weapon stockpiles following the fall of the Qadhafi regime. Experts have expressed similar concerns regarding the security and use of Syrian chemical weapons,
reportedly including stocks of nerve (sarin, VX) and blister (mustard gas) agents.
more
Accessed on 31.01.2020
Suivant les recommandations de la Stratégie Stop TB le Sénégal s’inscrit dans une optique de renforcement de la prise en charge de la tuberculose dans ce groupe vulnérable. Pour ce faire, la mise en place de documents standardisés et consensuels de référence, adap...tés au contexte sénégalais est indispensable. Ce guide s’adresse à tous les prestataires de soins impliqués dans la prise en charge des enfants. Il peut être utilisé aussi bien au niveau opérationnel qu’au niveau des hôpitaux.
more
La présente étude avait pour objectif principal de documenter la culture de l’utilisation des MI. Plus particulièrement, elle a documenté la valeur accordée aux différents moyens préventifs, en particulier la MI, les perceptions de l’utilité, du coût d’opportunité de leur utilisation... ; les modalités et logiques de leur attribution au sein des ménages. Elle s’est aussi intéressée aux obstacles à l’utilisation régulière des MI de même que les facteurs favorisants ; les habitudes des familles relatives à leur entretien, réparation et les modalités de leur usage en rapport avec les habitudes de couchage.
more
Ce guide qui s’adresse à tous les prestataires de soins impliqués dans la prise en charge des enfants, peut être utilisé aussi bien au niveau des structures sanitaires publiques que privées.
Son objectif général est d’améliorer la prise en charge de la tuberculose de l’enfant au Sé...négal et plus spécifiquement de :
• renforcer le dépistage précoce des cas de tuberculose infantile
• proposer une approche standardisée de diagnostic et de traitement de la tuberculose de l’enfant
• proposer une approche standardisée de gestion des cas contacts de tuberculose
• améliorer la prise en charge de la co-infection TB/VIH et de la tuberculose multirésistante de l’enfant
more
Antimicrobial resistance(AMR) poses a serious threat to human, animal and environmental health. Implementing ethical practice guidelines on how to use antimicrobials effectively and responsibly within the pig industry will contribute in reducing and preventing antimicro...bial resistance within the pig industry of South Africa. Members of Pig Vet Society (PVS) SA hereby commit themselvesto put these guidelines into good use in order to preserve the future and effectiveness of antimicrobials. PVS aims to be the leader in prevention of antimicrobial resistance and to encourage the pig industry to work together in achieving this.
more
The escalating antimicrobial resistance (AMR) pandemic is a global public health threat with extensive health, economic and societal implications. Resistance emerges because of selection pressure from rational and indiscriminate antimicrobial use in human health as well as in the veterinary, agricul...ture and environmental sectors. Infections caused by resistant bacteria result in longer duration of illness, higher mortality rates and increased costs associated with alternative treatment. AMR further constrains procedures that rely on antimicrobial prophylaxis, and AMR is recognized as a threat to theworld economy.
Journal of Public Health | Vol. 39, No. 1, pp. 8–13 | doi:10.1093/pubmed/fdw015 | Advance Access Publication March 3 2016
more
The National Department of Health and Department of Agriculture, Forestry and Fisheries have collectively engaged to determine the key interventions that will form the basis for this strategy taking into account the recommendations from the WHO and OIE.
The development and implementation of a Natio...nal Antimicrobial Resistance Strategy Framework that complements international efforts is a major step towards containment of the growing threat of antimicrobial resistance in human and animal health. Global partnerships need to be strengthened because the responsibility for reducing resistance is a shared one. This responsibility is not only limited to the health care sector, but calls for collaborative action in all sectors - human, animal and agriculture.
The National Antimicrobial Resistance Strategy Framework will affect South Africa’s response to this looming threat. We already have the tools and expertise to make a difference, now all we need is to work together toward a better future.
more
his practical Guide serves as a companion to the “WHO guideline: recommendations on digital interventions for health system strengthening” and provides a systematic process for countries to develop a costed implementation plan for digital health within one or more health programme areas, drawing... guidance from the WHO guideline–recommended digital health interventions, providing direction to ensure investments are needs-based and contribute effective and interoperable systems aligned with national digital architecture, country readiness, health system and policy goals.
more
The situation in South Sudan has proven to be unpredictable and volatile. New hotspots of violent conflict and civil unrest have continued to emerge and levels of severe acute food insecurity have become progressively worse. In addition to years of fighting and political instability, the country fac...es natural hazards, disease and pests, such as the desert locust, and the coronavirus disease 2019 (COVID-19) pandemic. Collectively, these risks have had and continue to have a catastrophic impact on the lives and livelihoods of South Sudanese, the majority of whom rely on agriculture, livestock, forestry and fisheries as their main source of income.
more
The cholera outbreak has affected 14 countries in the WHO African Region. The climate-induced natural disasters such as cyclone and flooding in the southern African region and drought in the Horn of Africa led to increase in cases of cholera in many of the affected countries. With the rainy season c...ommencement in the west African region there is risk of more cholera outbreaks on the horizon. The trend across the region is being closely monitored and this highlights the need for Member States to enhance readiness, heighten surveillance and institute preventive and control measures in communities and around border crossings to prevent and mitigate cross border infection. Since 1 January 2022, a cumulative number of 213 443 cholera cases has been reported to the WHO Regional Office for Africa (AFRO), including 3 951 deaths with a case fatality ratio (CFR) of 1.9% as of 16 July 2023 (Table 1). Malawi accounts for 28% (58 941) of the total cases and 45% (1 766) of all deaths reported, and together with Cameroon, Democratic Republic of the Congo, Mozambique, and Nigeria contribute to 85% (181 300) of the overall caseload and 88% (3 464) of cumulative deaths. In Epidemiologic week 28, six countries Burundi, Cameroon, Ethiopia, Kenya, Malawi and Mozambique reported a total of 667 new cases.
more
Les médicaments ont été classés à la fois par classe pharmaco-thérapeutique et par ordre alphabétique. La présence d’une marque astérisque renvoie à davantage de précision pour le (les) médicament(s) concerné(s).
Conformément aux recommandations de divers comités de l’Organisation mondiale de la Santé (OMS), le Bureau régional de l’OMS pour l’Afrique a mis en place trois initiatives phares afin de permettre aux États Membres de la Région africaine de se préparer aux urgences de santé publique, ...de les détecter et d’y riposter. Ces programmes sont le fruit de consultations approfondies avec plus de 30 Ministres africains, ainsi qu’avec des acteurs techniques, des partenaires à travers le continent et des institutions régionales telles que le Centre africain de contrôle et de prévention des maladies (CDC-Afrique), dont les contributions ont façonné les activités prioritaires. Le présent rapport est le quatrième rapport de synthèse trimestriel sur les progrès accomplis dans la mise en œuvre des initiatives phares.
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more